



Proactive Investor Meeting

23 November 2011

Silence's pedigree and vision




- Industry leader in RNAi therapeutics (a new drug class) and delivery
- Listed on LSE (AIM) with operations centralised in Berlin (30 FTEs, 10 PhDs)
- Commercially driven - reflected in recent appointments
- Strong validation through multiple partnerships supported by issued IP
- Building a strong pipeline targeting unmet medical needs with large commercial potential
- Commercialising the first blockbuster RNAi therapeutic



Outstanding potential of RNAi therapeutics

- Transforming technology
- Allows therapeutics intervention of previously 'undrugable' targets
 - 100% gene products can be blocked vs <20% previously
- RNA interference (RNAi) recognised by the Nobel Prize in 2006
- Proof of concept already demonstrated in man using Silence's technologies
- Commercial potential similar to monoclonal antibodies (sales 2010: US\$48bn)



Silence is the industry leader in RNAi delivery and therapeutic development



- Best-in-class RNAi (siRNA) therapeutics platform (“AtuRNAi”)
- Industry’s broadest clinical RNAi product pipeline
- Three breakthrough delivery platforms
- Significant progress of partnered pipeline
- Over 300 patients treated with AtuRNAi
- Very encouraging interim data for clinical Atu027 Phase I study

Breakthrough delivery technologies

AtuPLEX™

Blood vessels

Cancer & Metastases
(*Atu027, Atu134, Atu195*)



DACC

Lung blood vessels

Acute lung injury/ARDS
Pulmonary Hypertension
Infection & Inflammation
(*Atu111*)



















DBTC

Liver

Hepatocellular carcinoma
Ischemia Reperfusion Injury
Acute liver failure



Industry's broadest RNAi (siRNA) therapeutics clinical pipeline

Products	Partners	Target Tissue / Organ	Delivery method	Market size	Pre-Clinical	Phase I	Phase II
PF-4523655 <i>Diabetic Macular Edema</i>		RTP801 - Local Delivery to the Eye	Naked siRNA	\$1bn+ (potential)			
PF-4523655 <i>Age-related Macular Degeneration</i>		RTP801 - Local Delivery to the Eye	Naked siRNA	\$3.1bn (2010)			
QPI-1002 <i>Prevention of Delayed Graft Function</i>		P53 - Systemic Delivery to the Kidney	Naked siRNA	\$4.4bn (2010)			
QPI-1002 <i>Acute Kidney Injury</i>		P53 - Systemic Delivery to the Kidney	Naked siRNA	\$1bn+ (potential)			
Atu027 <i>Solid Tumors</i>		PKN3 - Systemic Delivery to Tumor Endothelium	AtuPLEX	\$8.2bn (angiogenesis mkt 2010)			
Atu134 <i>Solid Tumors</i>		Systemic Delivery to Tumor Endothelium	AtuPLEX	\$8.2bn (angiogenesis mkt 2010)			
Atu111 <i>Acute Lung Injury</i>		Systemic Delivery to Lung Endothelium	DACC	\$1bn+ (potential)			
Atu195 <i>Solid Tumors</i>		Systemic Delivery to Tumor Endothelium	AtuPLEX	\$8.2bn (angiogenesis mkt 2010)			

Five of 13 global clinical siRNA programs use Silence's AtuRNAi - over 300 patients treated

New medicine to treat various types of cancer: Encouraging clinical Atu027 data




- Atu027 Phase I interim data demonstrates safety (ASCO 2011)
- 10 out of 27 patients showed stable disease after treatment period
- Atu027 very well tolerated - effective dose exceeded
- Excellent preclinical efficacy data in a variety of cancer indications
- 28 of 33 patients treated to date
- Phase I results expected to report in mid-2012


Data not only validates Atu027 program but also AtuPLEX delivery platform

Atu027 in a prostate cancer model: Dose response

Prostate tumor volume



Volume of lymph node metastases




Dose-dependent inhibition of tumor growth and reduced lymph node metastasis


Atu027 possible deal structure

- Partnering discussions ongoing
- Typical deal structure
 - Upfronts (double digit \$m's)
 - Milestones (significant)
 - Royalties (double digit %)
- Variations
 - Global rights
 - Regional rights
 - Ex-US/Eu rights
 - Opt-in rights

Big Pharma alliances 2005-9




Early stage deals 2005-9



Significant progress of partnered pipeline

Encouraging Phase II results of PF-'655 (Diabetic Macular Edema) ✓

Phase IIb trial to be initiated in January 2012



Source: Quark

Phase II trial of PF-'655 (Age-related Macular Degeneration) completed, data expected H1 2012 ✓

Phase II trial of QPI-1002 (Prevention of Delayed Graft Function) completion in H1 2012

Phase II trial of QPI-1002 (Acute Kidney Injury) to be initiated shortly

Strong validation through partnerships



- AstraZeneca - \$15M upfront payment with up to \$400M in milestones plus sales royalties for five targets (2007, extended 2010)
- AstraZeneca - Novel approaches to delivery of siRNA molecules (2008, extended 2010)



- Pfizer/Quark - Phase II products for diabetic macular edema and age-related macular degeneration; \$95m milestones plus royalties, \$6m received (2006).



- Novartis/Quark - Phase II products for acute renal failure and kidney transplantation; \$82m in milestones plus royalties, \$1m received (2010).



- Dainippon Sumitomo - siRNA delivery collaboration, \$2m upfront (2009, expanded 2010)



- InterNA - microRNA delivery collaboration (9/2011)

Top 10 Pharma

- Top 10 Pharma co. - Delivery collaboration with DACC system (9/2011)



- Mirna - microRNA delivery collaboration (10/2011)

- Potential upcoming milestones from current partnerships - future milestones could be significant
 - Novartis: ~\$ 3-11 million (2012); total milestones \$82m
 - Pfizer: ~\$ 4 million (2014); total milestones \$95m
- Broad range of other income opportunities:
 - out-licensing/co-development of Atu027 or other internal candidates
 - research collaborations (e.g. AstraZeneca)
 - out-licensing of AtuRNAi technology (e.g. Pfizer/Quark, Novartis/Quark)
 - out-licensing of delivery technologies (AtuPLEX, DACC & DBTC)
 - delivery collaborations (e.g. Top-10 pharma, InteRNA, AstraZeneca, Dainippon Sumitomo)
- Case study - miRagen deal with Servier in microRNA
 - Signed 18 October 2011
 - US\$352m upfront and milestones
 - Total deal value of up to US\$1bn
 - Of which \$45m received over next three years
 - Double-digit royalties

Results for the six months ended 30 June 2011



£000s	1H11A ongoing	1H11A restructuring	1H11A reported	2010A
Revenue	354	-	354	2,366
R&D spend	(1,819)	-	(1,819)	(5,821)
Admin costs	(1,560)	(443)	(2,003)	(5,203)
Operating loss	(3,025)	(443)	(3,468)	(8,658)
Other income/(exp.)	42	-	42	(137)
Loss before tax	(2,983)	(443)	(3,426)	(8,795)
Loss after tax	(2,983)	(443)	(3,426)	(8,795)
Net cash			6,486	3,567

Funded well into H2 2012

Upcoming newsflow 2011/H12012

Update on PF-'655 in diabetic macular oedema (DME)	✓	Mar. 2011
Full year results for 2010	✓	April 2011
Fundraising	✓	May 2011
Present interim Phase I data of Atu027 at ASCO	✓	June 2011
Completion of Phase II trial of PF-'655 in AMD (Pfizer/Quark)	✓	July 2011
Multiple delivery agreements for microRNAs (e.g. InteRNA/miRNA)	✓	2H 2011
Top 10 Pharma DACC delivery agreement	✓	2H 2011
New Issuance of patents		2H 2011
Start of Phase II trial of QPI-1002 in AKI (Quark/Novartis)		2H 2011
Sign further collaborations agreements	ongoing	2H 2011-
Start of Phase IIb trial of PF-'655 in DME (Quark/Pfizer)		Jan. 2012
Completion of enrolment in Atu027 trial		1H 2012

How Silence views its key peers

	Silence	Alnylam	Arrowhead	Tekmira
Delivery technologies	3 proprietary delivery technologies (1 in Phase I) 5 delivery collaborations	1 delivery technology inlicensed from Tekmira 1 collaboration with MIT	5 proprietary delivery technologies of which 3 came from Roche	1 delivery technology stopped phase I due to safety problems
Immunosuppressive pretreatment required?	No	Yes	Unknown	Yes
Intellect. property siRNA + delivery	Issued composition of matter patents for siRNA	Issued composition of matter patents for siRNA Legal dispute with Tekmira	License from Alnylam via Roche	License from Alnylam Legal dispute with Alnylam
Clinical siRNA Pipeline	5 programs of which 4 are partnered	3 programs plus 2 partnered with Tekmira	1 program	3 programs of which 2 partnered with Alnylam
Validation through partnerships	4 Top 10 pharma companies + Dainippon Sumitomo + 2 microRNA companies	3 Top 10 pharma companies plus several other companies	None	Alnylam BMS
Listing	AIM	Nasdaq	Nasdaq	TSX
Market capitalisation, GBP	17m	203m	29m	13m
Cash (estimat.), GBP	5m	160m	6m	6m
Tech. value (estimat.), GBP	12m	43m	23m	7m

- Silence is the leader in RNAi therapeutic development and delivery
- RNAi therapeutics will become a major drug class
- Industry's broadest RNAi (siRNA) therapeutics clinical pipeline
- New medicine to treat various types of cancer: Encouraging Atu027 clinical data
- Partnered with four of top ten pharma companies
- Strong IP position with issued patents in all major markets

Share price contrasts significant progress



The statements made in this presentation may contain certain forward-looking comments. Actual events or results may differ from the Company's expectations. In addition to the matters described in the presentation, future actions by the European Agency for Evaluation of Medicinal Products, the U.S. Food and Drug Administration or equivalent regulatory authorities in other countries and results of pending or future clinical trials, as well as other risk factors outlined from time to time in the Company's regulatory filings, may affect actual results achieved by the Company. The Alternative Investment Market (AIM) has not reviewed and does not accept responsibility for the adequacy or accuracy of this presentation.

Delivering on the Promise of RNAi Therapeutics



Thank you